Eli Lil­ly CEO Ricks echoes a grow­ing re­frain on price ne­go­ti­a­tions: 'We’ll fo­cus our re­sources on oth­er ar­eas'

3 years ago
Pharma

Man­u­fac­tur­ing roundup: So­ci­etal CD­MO nets new cus­tomers; Chime Bi­o­log­ics gets the OK to man­u­fac­ture an­ti­bod­ies

3 years ago
Manufacturing

FDA is­sues new guid­ance for changes to dis­pos­able man­u­fac­tur­ing ma­te­ri­als

3 years ago
FDA+
Manufacturing

Ther­mo Fish­er com­pletes $76M cell cul­ture man­u­fac­tur­ing site near Buf­fa­lo, NY

3 years ago
Manufacturing

Green­Light Bio­sciences cel­e­brates man­u­fac­tur­ing mile­stone for Covid-19 boost­er can­di­date

3 years ago
Pharma
Coronavirus

Look­ing to bol­ster im­mune check­point R&D, Gilead buys Miro­Bio as it takes next-gen check­point ther­a­py to the clin­ic

3 years ago
Deals

FDA de­lays PDU­FA date for Lib­tayo lung can­cer com­bo; Swedish biotech hit flunks PhI­II for chemo-en­hanc­ing drug

3 years ago
News Briefing

David Hal­lal's El­e­vate­Bio launch­es new com­pa­ny to 'dis­rup­t' off-the-shelf cell ther­a­py, but pro­vides few oth­er ...

3 years ago
People
Startups

With SPAC­s' high tide long gone, Blue Wa­ter ditch­es sec­ond blank check voy­age

3 years ago
Financing
Deals

As­traZeneca part­ner Pieris ends work on HER2 drug test­ed in com­bo with Eli Lil­ly, Seagen can­cer meds

3 years ago
R&D

Weeks af­ter start­ing, Am­gen flash­es yel­low light on PhI­II of $400M eczema bet

3 years ago
R&D
Pharma

Am­gen chief Brad­way nabs a rare dis­ease play­er in $4B buy­out as the M&A tem­po ac­cel­er­ates

3 years ago
R&D

Pfiz­er ter­mi­nates PhI­II study of rare car­dio­vas­cu­lar drug picked up in $11.4B Ar­ray ac­qui­si­tion

3 years ago
R&D
Pharma

Af­ter get­ting hopes up, ex­pec­ta­tions on Gilead, Ar­cus' CD73 'dimmed' on new up­date

3 years ago
R&D

Tra­vere fails to con­vince reg­u­la­tors to con­sid­er ac­cel­er­at­ed ap­proval for a rare kid­ney dis­ease — again

3 years ago
R&D
FDA+

Two CD­MOs come to­geth­er as they look to ex­pand their reach in cell ther­a­py man­u­fac­tur­ing

3 years ago
Deals
Cell/Gene Tx

Sofinno­va, For­bion back $70M push across fin­ish line for rare an­ti­fun­gal treat­ment

3 years ago
Financing

CDC, NIH, FDA lead­ers call for US-based clin­i­cal tri­al of small­pox drug in treat­ing mon­key­pox

3 years ago
R&D
FDA+

Co­herus pulls first in­ter­change­able biosim­i­lar win for Lu­cen­tis copy­cat

3 years ago
Pharma
FDA+

Hori­zon low­ers ex­pec­ta­tions for Te­pez­za and ad­justs its strat­e­gy for the year ahead

3 years ago
R&D
Pharma

As a hand­ful of com­pa­nies spin out health busi­ness­es, Ger­many's Schott glass­mak­er looks to get in on the ac­tion

3 years ago
Manufacturing

Sales of Boehringer In­gel­heim's di­a­betes, pul­monary drugs jump with­in $11B+ first-half to­tal

3 years ago
Pharma

Mod­er­na CEO Ban­cel hits the gas with vari­ant-spe­cif­ic boost­ers and a very ear­ly mon­key­pox pro­gram un­der­way

3 years ago
Pharma

Drug pro­mo­tion en­force­ment so far sim­i­lar un­der new FDA chief, with just 4 let­ters in first half of 2022

3 years ago
Pharma
FDA+
First page Previous page 479480481482483484485 Next page Last page
A service from the Financial Times